查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1634211

全球性傳染病 (STD) 診斷市場 - 2025 - 2033

Global Sexually Transmitted Diseases (STD) Diagnostics Market - 2025 - 2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年，全球性傳染病 (STD) 診斷市場規模達到 106 億美元，預計到 2033 年將達到 194 億美元，2025-2033 年預測期間複合年成長率為 7.1%。

性傳染病 (STD) 診斷是指用於檢測、識別和確認個人是否存在性傳染感染 (STI) 的醫療流程和技術。這些疾病主要透過性接觸傳播，可能由細菌、病毒或寄生蟲引起。性病診斷涵蓋廣泛的實驗室檢查、臨床評估和篩檢方法，以在早期階段（甚至在症狀出現之前）檢測感染，以便及時治療並降低傳播給他人的風險。

對性傳染病 (STD) 診斷的需求是由多種因素推動的，從性健康意識的提高到診斷技術的進步。例如，根據世界衛生組織估計，2020 年，四種性傳染病之一的滴蟲病（1.56 億）、淋病（8,200 萬）、梅毒（710 萬）和衣原體（1.29 億）的新病例在2020 年發生了3.74 億例。這些不斷增加的性病增加了對性病診斷的需求。

市場動態：

驅動程式和限制

性病自我診斷不斷進步

STD 自我診斷的不斷進步極大地推動了性傳染病 (STD) 診斷市場的成長，預計將在預測期內推動該市場的發展。性傳染病自我檢測套件允許個人在家中進行檢測，無需醫療保健專業人員，使過程更加方便和私密。這一趨勢對於減少與性病檢測相關的恥辱尤其重要。

例如，新斯科細亞省愛滋病聯盟負責人表示，新斯科細亞省將於 2024 年 8 月提供免費的性傳染感染家庭檢測，這是減少重要性保健障礙的重要一步。

此外，2023 年6 月，LifeCell International 推出了檢測試劑盒，讓患者在家中私密地收集細胞拭子和組織樣本，然後用於檢測人類乳突病毒(HPV)，這種病毒會導致女性子宮頸癌和性傳染感染，例如梅毒或淋病。

現代自診斷測試旨在提供快速結果，這是市場的重要驅動力。用戶可以在 20 分鐘到 1 小時內獲得測試結果，這對於尋求即時答案的人來說更具吸引力。例如，OraQuick 提供快速 HIV 檢測，無需實驗室設備即可在 20 分鐘內得出結果。這些測試的速度和簡便性使其越來越受歡迎，因為個人更有可能使用提供快速回饋的測試。

認知和教育有限

認知和教育有限是性傳染病 (STD) 診斷市場成長的重大障礙。儘管診斷技術不斷進步，檢測選擇範圍不斷擴大，但對性病檢測重要性的認知不足以及性健康教育的缺乏阻礙了診斷服務的廣泛採用。

許多人不知道與性病相關的風險，尤其是可能被忽視的無症狀感染。這種意識的缺乏導致檢測率低，特別是對於那些可能不認為自己處於危險之中的人群。例如，根據疾病預防控制中心的數據，美國近五分之一的人患有性病，但許多人由於不尋求檢測而仍未被診斷出來。這種情況在披衣菌和淋病等感染中尤其常見，這些感染通常沒有任何症狀。

許多人因為害怕受到侮辱而避免性病檢測，即使他們知道檢測的必要性。在保守社會中尤其如此，討論性健康是禁忌。例如，在印度，文化規範不鼓勵公開談論性健康，這導致檢測率較低。 《印度公共衛生雜誌》的一項研究顯示，超過 50% 的受訪年輕人由於擔心社會恥辱而不願尋求醫療建議或性傳染病檢測。

目錄

第1章：市場介紹和範圍

  • 報告的目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類的片段
  • 依疾病類型分類
  • 按診斷測試類型分類的片段
  • 最終使用者的片段
  • 按地區分類的片段

第 3 章：動力學

  • 影響因素
    • 促進要素
      • 性病自我診斷的不斷進步
    • 限制
      • 意識和教育有限
    • 機會
    • 影響分析

第 4 章：策略洞察與產業展望

  • 市場領導者和先驅
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的知名領導者
    • 擁有成熟產品的市場領導者
  • 新興新創企業和關鍵創新者
  • CXO 觀點
  • 最新進展和突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：性傳染病 (STD) 診斷市場（按產品類型）

  • 儀器儀表
  • 耗材
  • 軟體

第 6 章：性傳染病 (STD) 診斷市場（按疾病類型）

  • 衣原體
  • 生殖器皰疹
  • 淋病
  • B型肝炎
  • 愛滋病毒/愛滋病
  • 人類乳突病毒 (HPV)
  • 梅毒
  • 其他

第 7 章：性傳染病 (STD) 診斷市場（按診斷測試類型）

  • 分子測試
  • 血清學測試
  • 即時護理 (PoC) 測試
  • 其他

第 8 章：性傳染病 (STD) 診斷市場（按最終用戶）

  • 醫院
  • 專科診所
  • 診斷實驗室
  • 家庭護理設置
  • 其他

第 9 章：性傳染病 (STD) 診斷市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的主要發展
  • 公司基準化分析

第 11 章：公司簡介

  • Abbott Laboratories
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
    • SWOT分析
  • Becton, Dickinson, and Company
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Hologic, Inc.
  • QIAGEN NV
  • Diasorin SpA
  • Seegene Inc.
  • Bosch Healthcare Solutions GmbH

第 12 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 13 章：附錄

簡介目錄
Product Code: CD1785

The global Sexually Transmitted Diseases (STD) diagnostics market reached US$ 10.6 billion in 2024 and is expected to reach US$ 19.4 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033.

Sexually Transmitted Diseases (STD) diagnostics refers to the medical processes and technologies used to detect, identify and confirm the presence of sexually transmitted infections (STIs) in individuals. These diseases are primarily transmitted through sexual contact and can be caused by bacteria, viruses, or parasites. STD diagnostics encompasses a wide range of laboratory tests, clinical evaluations and screening methods to detect infections in their early stages, even before symptoms appear, allowing for timely treatment and reducing the risk of transmission to others.

The demand for sexually transmitted diseases (STD) diagnostics is driven by a variety of factors, ranging from increasing awareness of sexual health to advancements in diagnostic technology. For instance, according to WHO estimates, 374 million new cases of one of the four STIs trichomoniasis (156 million), gonorrhea (82 million), syphilis (7.1 million), and chlamydia (129 million) occurred in 2020. An estimated 300 million women are infected with HPV, the main cause of anal and cervical cancer in males who have sex with men. These rising STDs increase the demand for STD diagnostics.

Market Dynamics: Drivers & Restraints

Rising advancements in STD self-diagnostics

The rising advancements in STD self-diagnostics are significantly driving the growth of the sexually transmitted diseases (STD) diagnostics market and are expected to drive the market over the forecast period. Self-testing kits for STDs allow individuals to test at home without the need for a healthcare professional, making the process more convenient and private. This trend has been particularly important in reducing the stigma associated with STD testing.

For instance, in August 2024, Nova Scotia is going to offer free at-home tests for sexually transmitted infections is an important step toward reducing some barriers to vital sexual health care, says the head of the provincial AIDS coalition.

Additionally, in June 2023, LifeCell International launched test kits that allow patients to collect cell swabs and tissue samples in the privacy of their homes that can then be used for detecting Human Papillomavirus (HPV) which causes cervical cancer in women and sexually transmitted infections like syphilis or gonorrhea.

Modern self-diagnostic tests are designed to provide rapid results, which is a significant driver in the market. Users can get test results in 20 minutes to 1 hour, making it more attractive for those seeking immediate answers. For instance, OraQuick offers a rapid HIV test that delivers results in 20 minutes with no need for laboratory equipment. The speed and ease of these tests contribute to their growing popularity, as individuals are more likely to use tests that provide quick feedback.

Limited awareness and education

Limited awareness and education are significant barriers to the growth of the sexually transmitted diseases (STD) diagnostics market. Despite advances in diagnostic technologies and an increasing range of testing options, insufficient understanding of the importance of STD testing and a lack of education about sexual health have hindered the widespread adoption of diagnostic services.

Many individuals are unaware of the risks associated with STDs, especially asymptomatic infections that can go unnoticed. This lack of awareness leads to low testing rates, especially in populations who might not perceive themselves as being at risk. For instance, according to the CDC, nearly 1 in 5 people in the U.S. are living with an STD, but many remain undiagnosed because they do not seek testing. This is particularly common with infections like chlamydia and gonorrhea, which often present with no symptoms.

Many individuals avoid STD testing due to fear of being stigmatized, even if they are aware of the need for testing. This is particularly true in conservative societies where discussions about sexual health are taboo. For instance, in India, cultural norms discourage open conversations about sexual health, which results in lower testing rates. According to a study by the Indian Journal of Public Health, over 50% of young people surveyed were unwilling to seek medical advice or testing for STDs due to fear of social stigma.

Segment Analysis

The global sexually transmitted diseases (STD) diagnostics market is segmented based on product type, disease type, diagnostic test type, end-user and region.

Disease Type:

The chlamydia segment is expected to dominate the sexually transmitted diseases (STD) diagnostics market share

Chlamydia is one of the most common STDs globally, particularly affecting young adults and adolescents. The Centers for Disease Control and Prevention (CDC) estimates that over 1.8 million new cases of chlamydia are reported annually in the United States alone, making it the most frequently reported STD in the country.

Chlamydia is often asymptomatic, particularly in women, leading to high rates of undiagnosed cases. This makes regular testing crucial, especially among sexually active individuals who may not be aware they are infected. As a result, the demand for routine screening and diagnostic tests increases. Thus, many market players are advancing STD diagnostics for chlamydia testing.

For instance, in May 2024, Sherlock Bio started testing its over-the-counter fast test for identifying STIs including chlamydia, with its plans to sell it by the middle of 2025. In order to compare the accuracy of their CRISPR-based test to widely used lab tests for chlamydia, the business intends to enlist 2,500 sexually active volunteers at 20 research locations around the United States.

Because Chlamydia is highly treatable with antibiotics, early detection and treatment are key to preventing long-term health complications. Many health authorities, including the CDC and the U.S. Preventive Services Task Force (USPSTF), recommend routine screening for Chlamydia for sexually active women under the age of 25 and for individuals in high-risk groups.

Geographical Analysis

North America is expected to hold a significant position in the sexually transmitted diseases (STD) diagnostics market share

North America, especially the United States, has one of the highest rates of sexually transmitted diseases globally. The Centers for Disease Control and Prevention (CDC) reports that more than 2.5 million cases of chlamydia, gonorrhea, and syphilis were diagnosed in the United States between 2020 to 2021. The high incidence of STDs in this region drives the demand for diagnostic tests.

The U.S. has also seen significant challenges with HIV, a key part of the STD landscape. According to HIV.gov, more than 1.2 million Americans are currently living with HIV and many more are at risk of HIV infection. According to the CDC, around 38,000 people in the U.S. are diagnosed with HIV annually, contributing to the demand for regular HIV testing and diagnostics.

North America benefits from strong public health policies that promote regular STD testing, early diagnosis, and treatment. The CDC and other organizations run numerous programs aimed at increasing awareness and access to STD diagnostics. For instance, the "Get Yourself Tested" (GYT) campaign, which encourages young people to get tested for STDs, has significantly increased awareness and testing uptake, particularly among sexually active youth. This initiative has led to a greater demand for diagnostic services and kits.

North America leads in the adoption of advanced diagnostic technologies for STDs. Technologies such as at-home diagnostic kits, rapid diagnostic tests and point-of-care tests are widely used across the region due to their accuracy, ease of use, and quick results.

For instance, in August 2023, the iHealth Labs, Inc. (iHealth) Home Collection Kit for HIV and syphilis testing was released. In the privacy of their own home, anybody over the age of 18 can get a blood sample for testing for syphilis and HIV (I, II, and P24 antigen) using the FDA-approved solution. They can mail the sample to the lab with a pre-paid overnight label and receive accurate and private results in as little as two days. As the STD issue in the United States grew, iHealth responded by launching the first home collection solution in the STD OTC test category.

Asia-Pacific is growing at the fastest pace in the sexually transmitted diseases (STD) diagnostics market

The Asia-Pacific region, home to more than 4.5 billion people, has seen an alarming rise in the incidence of sexually transmitted diseases. According to the World Health Organization (WHO), Asia accounts for a significant percentage of global STD cases. In China, India, and Thailand, the incidence of STDs like chlamydia, gonorrhea, and syphilis is increasing, especially among young people and high-risk groups.

For instance, according to the National Institute of Health (NIH), globally, there are 376 million new cases of four curable STDs (chlamydia, gonorrhea, syphilis, and trichomoniasis) each year, with a significant portion occurring in Asia. In India, syphilis and chlamydia are among the most common STDs, leading to an increased need for diagnostic tests.

Over the past decade, there has been a growing awareness of sexual health issues, including the importance of STD testing, in many parts of Asia. This is primarily driven by global health campaigns, educational initiatives, and increased media coverage of STDs and HIV/AIDS prevention. For instance, In India, public health campaigns, such as those run by the India HIV/AIDS Alliance and Population Foundation of India, have been instrumental in spreading awareness about STDs and HIV, encouraging people to get tested, leading to more frequent testing and demand for diagnostic services.

Additionally, several governments in the Asia-Pacific region have recognized the importance of combating STDs and are investing in prevention, education, and diagnostic services. The Indian government, for instance, has launched the National AIDS Control Programme (NACP), which offers free testing and treatment for HIV, syphilis, and other STDs in many public health centers.

Competitive Landscape

The major global players in the sexually transmitted diseases (STD) diagnostics market include Abbott Laboratories, Becton, Dickinson, and Company, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Hologic, Inc., QIAGEN N.V., Diasorin S.p.A., Seegene Inc., Bosch Healthcare Solutions GmbH and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global sexually transmitted diseases (STD) diagnostics market report delivers a detailed analysis with 70 key tables, more than 70 visually impactful figures, and 188 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Disease Type
  • 2.5. Snippet by Diagnostic Test Type
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in STD Self-Diagnostics
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Awareness and Education
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Sexually Transmitted Diseases (STD) Diagnostics Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Instruments*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Consumables
  • 5.4. Software

6. Sexually Transmitted Diseases (STD) Diagnostics Market, By Disease Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 6.1.2. Market Attractiveness Index, By Disease Type
  • 6.2. Chlamydia*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Genital Herpes
  • 6.4. Gonorrhea
  • 6.5. Hepatitis B
  • 6.6. HIV/AIDS
  • 6.7. Human papillomavirus (HPV)
  • 6.8. Syphilis
  • 6.9. Others

7. Sexually Transmitted Diseases (STD) Diagnostics Market, By Diagnostic Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 7.1.2. Market Attractiveness Index, By Diagnostic Test Type
  • 7.2. Molecular Tests*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Serologic Tests
  • 7.4. Point-of-Care (PoC) Tests
  • 7.5. Others

8. Sexually Transmitted Diseases (STD) Diagnostics Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Specialty Clinics
  • 8.4. Diagnostic Laboratories
  • 8.5. Homecare Settings
  • 8.6. Others

9. Sexually Transmitted Diseases (STD) Diagnostics Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. Abbott Laboratories*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. Becton, Dickinson, and Company
  • 11.3. F. Hoffmann-La Roche Ltd.
  • 11.4. Bio-Rad Laboratories, Inc.
  • 11.5. Thermo Fisher Scientific Inc.
  • 11.6. Hologic, Inc.
  • 11.7. QIAGEN N.V.
  • 11.8. Diasorin S.p.A.
  • 11.9. Seegene Inc.
  • 11.10. Bosch Healthcare Solutions GmbH

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us